The FDA has Issued a Complete Response Letter to Xspray Pharma Delaying Approvals Affecting ALL and CML
Xspray Pharma, the developer of the drug dasatinib, was recently issued a Complete Response Letter (CRL) by the FDA while waiting for corrective actions, according to Cancer Network. Based on…